PT Itama Ranoraya Tbk (IRRA.JK)
IDR 396.0
(-0.5%)
IDR 396.0
(-0.5%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 240.86 Billion IDR | 50.34% |
| 2022 | 160.2 Billion IDR | 100.26% |
| 2021 | 80 Billion IDR | 16479.92% |
| 2020 | 482.51 Million IDR | 0.0% |
| 2019 | - IDR | -100.0% |
| 2018 | 4.84 Billion IDR | 239.8% |
| 2017 | 1.42 Billion IDR | -46.6% |
| 2016 | 2.66 Billion IDR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 205.75 Billion IDR | -14.57% |
| 2024 Q2 | 221.29 Billion IDR | 7.55% |
| 2024 Q3 | 225.75 Billion IDR | 39.85% |
| 2023 Q3 | 198.3 Billion IDR | 67.54% |
| 2023 Q2 | 118.36 Billion IDR | 14.12% |
| 2023 FY | 240.86 Billion IDR | 50.34% |
| 2023 Q1 | 103.71 Billion IDR | -35.26% |
| 2023 Q4 | 240.86 Billion IDR | 21.46% |
| 2022 Q2 | 76.37 Billion IDR | -44.87% |
| 2022 Q4 | 160.2 Billion IDR | 178.93% |
| 2022 Q3 | 57.43 Billion IDR | -24.8% |
| 2022 Q1 | 138.54 Billion IDR | 73.19% |
| 2022 FY | 160.2 Billion IDR | 100.26% |
| 2021 Q1 | 232.51 Million IDR | -51.81% |
| 2021 FY | 80 Billion IDR | 16479.92% |
| 2021 Q4 | 80 Billion IDR | 166.67% |
| 2021 Q3 | 30 Billion IDR | -65.17% |
| 2021 Q2 | 86.12 Billion IDR | 36942.27% |
| 2020 FY | 482.51 Million IDR | 0.0% |
| 2020 Q4 | 482.51 Million IDR | -97.59% |
| 2020 Q3 | 20 Billion IDR | -66.67% |
| 2020 Q2 | 60 Billion IDR | 500.0% |
| 2020 Q1 | 10 Billion IDR | 0.0% |
| 2019 Q4 | - IDR | 0.0% |
| 2019 Q1 | 4.09 Billion IDR | 0.0% |
| 2019 FY | - IDR | -100.0% |
| 2018 FY | 4.84 Billion IDR | 239.8% |
| 2018 Q1 | - IDR | 0.0% |
| 2017 FY | 1.42 Billion IDR | -46.6% |
| 2016 FY | 2.66 Billion IDR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| PT Enseval Putera Megatrading Tbk. | 3.08 Billion IDR | -7697.907% |
| PT Kimia Farma (Persero) Tbk | 7926.98 Billion IDR | 96.961% |
| PT Millennium Pharmacon International Tbk | 710.33 Billion IDR | 66.092% |
| PT Soho Global Health Tbk | 19.94 Billion IDR | -1107.507% |